Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

201.54 +2.44 (+1.23%)
Streaming Delayed Price Updated: 10:17 AM EDT, Jun 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
60 61 Next >
News headline image
Biogen Just Reached a Big Milestone. Why Isn't the Stock Rising? ↗
Biogen shares are little changed year to date. 
Via The Motley Fool
News headline image
Mixed Jobs Data; Fed Governors Want More Interest Rate Hikes; US, China Spat Rattles Semiconductor Sector: The Week In The Markets ↗
 
Via Benzinga
News headline image
If You Invested $1000 In This Stock 15 Years Ago, You Would Have $4,900 Today ↗
 
Via Benzinga
News headline image
Expanded Medicare Coverage For Biogen-Eisai's Leqembi Signals a Turning Point in Alzheimer's Treatment: Analysts ↗
The FDA approved a supplemental marketing application for Biogen Inc (NASDAQ: BIIB)-Eisai Co Ltd (OTC: ESALY) supporting the traditional approval of Leqembi (lecanemab-irmb), making it the first and... 
Via Benzinga
News headline image
FDA Approves Biogen's Alzheimer's Drug: Here Are Other Companies With Treatments In The Pipeline ↗
The FDA fully approved Biogen Inc.’s (NASDAQ: BIIB) Alzheimer’s treatment Leqembi on Thursday, becoming the first Alzheimer’s antibody treatment to reach full approval. 
Via Benzinga
News headline image
What 29 Analyst Ratings Have To Say About Biogen ↗
 
Via Benzinga
News headline image
What's Going On With Biogen Stock Thursday ↗
Biogen Inc (NASDAQ: BIIB) shares were flat in Thursday's after-hours session after falling marginally by 0.31% to $284.99 during  
Via Benzinga
News headline image
Stock Market Rally Pulls Back As Yields Jump; Tesla, Meta In Focus: Weekly Review ↗
Automakers rallied on sales while Meta's Threads had a big launch. 
Via Investor's Business Daily
News headline image
FSLR Stock Alert: The $1 Billion Reason First Solar Is Up Today ↗
First Solar (FSLR) stock is rising higher on Friday after the solar energy company announced a $1 billion revolving credit facility. 
Via InvestorPlace
News headline image
Why Is Alibaba (BABA) Stock Up Today? ↗
Alibaba (BABA) stock is on the rise Friday as investors react to a few pieces of news considering the Chinese e-commerce giant. 
Via InvestorPlace
News headline image
BIIB Stock Alert: What to Know as FDA Approves Biogen’s Alzheimer’s Drug ↗
Biogen (BIIB) stock is in the news Friday after the pharmaceutical company got approval from the FDA for its Alzheimer's drug. 
Via InvestorPlace
News headline image
Stock Futures Dip As Traders Eye Friday Jobs Report: Analyst Says Q3 Returns Hinge More On This Catalyst Than Fed Move ↗
 
Via Benzinga
News headline image
How Is The Market Feeling About Biogen? ↗
 
Via Benzinga
News headline image
A Look Into Biogen Inc's Price Over Earnings ↗
 
Via Benzinga
News headline image
$1000 Invested In Biogen 15 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Top 5 Trending Stocks: Prestige Wealth's IPO, Rivian's Lawsuit, Meta's New Platform, Tesla's Dip, And Biogen's FDA Approval ↗
 
Via Benzinga
News headline image
FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
News headline image
3 Biotech Stocks to Make Your ‘Get Rich’ Dreams Come True ↗
These high return biotech stocks offer tremendous upside ahead and are likely to soar on the back of several growth drivers 
Via InvestorPlace
News headline image
Biogen's Make-Or-Break Moment Is Here In Alzheimer's Treatment ↗
The FDA is expected to announce Thursday whether it has approved or rejected Biogen's Alzheimer's drug. 
Via Investor's Business Daily
News headline image
Biogen Reports New Spinraza Data In Atrophy Patients After Incomplete Response To Novartis' Treatment ↗
Biogen Inc (NASDAQ: BIIB) announced new Spinraza (nusinersen) data that were presented at the SMA Research & Clinical Care Meeting  
Via Benzinga
News headline image
Does This Signal Trouble for Biogen's New Alzheimer's Drug? ↗
Biogen is counting on Leqembi to boost its revenue growth. 
Via The Motley Fool
News headline image
New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy
From Biogen Inc.
Via GlobeNewswire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Amgen Inc. Dividend Stock Analysis ↗
The company has paid a cash dividend to shareholders every year since 2011 and has increased its dividend payments for 13 consecutive years. 
Via Talk Markets
News headline image
Is This a Sign That Biogen's Leqembi Could Obtain FDA Approval Next Month? ↗
The catalyst many Biogen investors have been waiting for may soon arrive. 
Via The Motley Fool
News headline image
Alleged Industrial Espionage Makes an Interesting Story ↗
We also chat about Vertex Pharmaceuticals and its role at the center of cystic fibrosis treatment. 
Via The Motley Fool
News headline image
5 Biotech Stocks That Could Soar Thanks To These Disruptive Healthcare Technologies ↗
 
Via Benzinga
News headline image
How to Retire Rich: Biotech Stocks Edition ↗
Thanks to its enormous and practically permanent relevancies, the biotech sector offers a great avenue for retirement planning stocks. 
Via InvestorPlace
News headline image
2 Market-Beating Stocks With Major Catalysts on the Way ↗
Can these companies keep climbing? 
Via The Motley Fool
News headline image
7 Undervalued S&P 500 Stocks to Buy in June ↗
If you want to maximize your upside potential in a relatively predictable arena, these undervalued S&P 500 stocks could be for you. 
Via InvestorPlace
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
60 61 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.